Trials / Unknown
UnknownNCT03603938
Bedtime Potassium Losartan on CKD With Nocturnal Hypertension Patients With Nondipping Blood Pressure Pattern
Effect of Potassium Losartan With Bedtime Dosing on Chronic Kidney Disease Patients With Nondipping Blood Pressure Pattern
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 189 (estimated)
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University · Academic / Other
- Sex
- All
- Age
- 14 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Nondipping blood pressure (BP) pattern is a potential independent risk factor for chronic kidney disease (CKD). Whether bedtime administration of potassium losartan has benefit for anti-hypertension and the prognosis of CKD patients is not clear. Patients with nondipping BP pattern or dipping BP pattern were enrolled in this study, and the patients with nondipping BP pattern were randomly divided into two groups and treated with bedtime or awakening doses of potassium losartan.
Detailed description
Patients with nondipping BP pattern or dipping BP pattern were enrolled in this study, and the patients with nondipping BP pattern were randomly divided into two groups and treated with bedtime or awakening doses of potassium losartan. Any patients who had any antihypertension medication at bedtime would withdrawal the drugs for 2 weeks before ABPM. Patients with nondipping BP were then randomly divided into two groups and received a bedtime or awakening dose of potassium losartan. Patients with dipping BP were called the dipper group, while the patients with nondipping BP were called the awakening dose group or bedtime dose group, according to the time of drug administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | potassium losartan | treated with bedtime or awakening doses of potassium losartan |
Timeline
- Start date
- 2018-11-01
- Primary completion
- 2023-06-30
- Completion
- 2023-12-30
- First posted
- 2018-07-27
- Last updated
- 2018-07-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03603938. Inclusion in this directory is not an endorsement.